The drug maker says its treatment of a rare kidney disease met its main goal in a late-stage trial.
Vertex has the revenue power to excel during any market environment.
The company got into the game by partnering with smaller drugmakers in this field, most notably CRISPR Therapeutics. The two ...
The company has several juicy growth opportunities ahead of it, a market professional tracking its fortunes believes.
Among pharmaceutical industry investors, Vertex Pharmaceuticals (VRTX +0.90%) is a broadly popular stock thanks to its impressive year-over-year quarterly earnings growth of 124.4% and its proven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results